ERNEXA THERAPEUTICS INC (ERNA) Fundamental Analysis & Valuation

NASDAQ:ERNA • US1140823089

Current stock price

0.2093 USD
0 (-2.2%)
Last:

This ERNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ERNA Profitability Analysis

1.1 Basic Checks

  • ERNA had negative earnings in the past year.
  • ERNA had a negative operating cash flow in the past year.
  • In the past 5 years ERNA always reported negative net income.
  • ERNA had a negative operating cash flow in each of the past 5 years.
ERNA Yearly Net Income VS EBIT VS OCF VS FCFERNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • ERNA's Return On Assets of -241.67% is on the low side compared to the rest of the industry. ERNA is outperformed by 91.30% of its industry peers.
  • ERNA has a Return On Equity of -587.21%. This is in the lower half of the industry: ERNA underperforms 78.53% of its industry peers.
Industry RankSector Rank
ROA -241.67%
ROE -587.21%
ROIC N/A
ROA(3y)-377.14%
ROA(5y)-326.11%
ROE(3y)-1392.56%
ROE(5y)-972.29%
ROIC(3y)N/A
ROIC(5y)N/A
ERNA Yearly ROA, ROE, ROICERNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K -2.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ERNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERNA Yearly Profit, Operating, Gross MarginsERNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ERNA Health Analysis

2.1 Basic Checks

  • ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ERNA has more shares outstanding
  • ERNA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ERNA is higher compared to a year ago.
ERNA Yearly Shares OutstandingERNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
ERNA Yearly Total Debt VS Total AssetsERNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -63.12, we must say that ERNA is in the distress zone and has some risk of bankruptcy.
  • ERNA has a worse Altman-Z score (-63.12) than 92.26% of its industry peers.
  • There is no outstanding debt for ERNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -63.12
ROIC/WACCN/A
WACC7.49%
ERNA Yearly LT Debt VS Equity VS FCFERNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

2.3 Liquidity

  • ERNA has a Current Ratio of 1.01. This is a normal value and indicates that ERNA is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of ERNA (1.01) is worse than 86.65% of its industry peers.
  • ERNA has a Quick Ratio of 1.01. This is a normal value and indicates that ERNA is financially healthy and should not expect problems in meeting its short term obligations.
  • ERNA has a worse Quick ratio (1.01) than 85.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
ERNA Yearly Current Assets VS Current LiabilitesERNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ERNA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 97.07% over the past year.
  • ERNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)97.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERNA Yearly Revenue VS EstimatesERNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2024 5M 10M 15M 20M 25M
ERNA Yearly EPS VS EstimatesERNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 0 -500 -1K -1.5K -2K

More info and screens

Find the best growth stocksShow best growing peers

0

4. ERNA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ERNA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERNA Price Earnings VS Forward Price EarningsERNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERNA Per share dataERNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ERNA Dividend Analysis

5.1 Amount

  • ERNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ERNA Fundamentals: All Metrics, Ratios and Statistics

ERNEXA THERAPEUTICS INC

NASDAQ:ERNA (4/8/2026, 12:04:52 PM)

0.2093

0 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-05
Inst Owners1.81%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change0%
Market Cap6.10M
Revenue(TTM)N/A
Net Income(TTM)-14.10M
Analysts43.33
Price TargetN/A
Short Float %0.47%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.54
P/tB 17.09
EV/EBITDA N/A
EPS(TTM)-3.25
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.08
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -241.67%
ROE -587.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-377.14%
ROA(5y)-326.11%
ROE(3y)-1392.56%
ROE(5y)-972.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z -63.12
F-Score4
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)115%
Cap/Depr(5y)131.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.89%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.69%
OCF growth 3YN/A
OCF growth 5YN/A

ERNEXA THERAPEUTICS INC / ERNA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ERNEXA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ERNA.


Can you provide the valuation status for ERNEXA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ERNEXA THERAPEUTICS INC (ERNA). This can be considered as Overvalued.


Can you provide the profitability details for ERNEXA THERAPEUTICS INC?

ERNEXA THERAPEUTICS INC (ERNA) has a profitability rating of 0 / 10.


How financially healthy is ERNEXA THERAPEUTICS INC?

The financial health rating of ERNEXA THERAPEUTICS INC (ERNA) is 4 / 10.


Can you provide the dividend sustainability for ERNA stock?

The dividend rating of ERNEXA THERAPEUTICS INC (ERNA) is 0 / 10 and the dividend payout ratio is 0%.